Abiopharma

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

FDA approve DELGOCITINIB

FDA approve RAMIPRIL

Castle Biosciences - Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

Bristol Myers Squibb - Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

New Form 6-K - DR REDDYS LABORATORIES LTD Filed: 2025-07-25 AccNo: 0001575872-25-000506 Size: 1 MB

Sensient Technologies Corporation - Sensient Technologies Corporation Reports Results for the Quarter Ended June 30, 2025

New Form 6-K - DR REDDYS LABORATORIES LTD Filed: 2025-07-25 AccNo: 0001575872-25-000504 Size: 6 MB

European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors

Trixeo Aerosphere receives positive EU CHMP opinion as first inhaled medicine using next-generation propellant with near-zero Global Warming Potential

AirSculpt Technologies Announces Second Quarter Fiscal 2025 Earnings Release Date and Conference Call

Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimers disease

New Form 8-K - ImmunityBio, Inc. Filed: 2025-07-25 AccNo: 0001193125-25-164789 Size: 764 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits